

Saint Lucia

Population 2016

<1 million

| Estimates of TB burden*, 2016 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB) | <0.01 (<0.01–<0.01) | 2.2 (1.8–2.6) |
| Mortality (HIV+TB only) | <0.01 (<0.01–<0.01) | 0.1 (0.07–0.14) |
| Incidence (includes HIV+TB) | <0.01 (<0.01–<0.01) | 1.9 (1.7–2.2) |
| Incidence (HIV+TB only) | <0.01 (<0.01–<0.01) | 0.65 (0.42–0.92) |
| Incidence (MDR/RR-TB)** | 0 (0–0) | 0 (0–0) |

Estimated TB incidence by age and sex (thousands)*, 2016

| | 0-14 years | > 14 years | Total |
|---------|------------|---------------------|---------------------|
| Females | 0 (0–0) | <0.01 (<0.01–<0.01) | <0.01 (<0.01–<0.01) |
| Males | 0 (0–0) | <0.01 (<0.01–<0.01) | <0.01 (<0.01–<0.01) |
| Total | 0 (0–0) | <0.01 (<0.01–<0.01) | <0.01 (<0.01–<0.01) |

TB case notifications, 2016

| | |
|--|------|
| Total cases notified | 3 |
| Total new and relapse | 3 |
| - % tested with rapid diagnostics at time of diagnosis | |
| - % with known HIV status | 100% |
| - % pulmonary | 100% |
| - % bacteriologically confirmed among pulmonary | 100% |

Universal health coverage and social protection

| | |
|--|--------------|
| TB treatment coverage (notified/estimated incidence), 2016 | 87% (75–100) |
| TB patients facing catastrophic total costs | |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | null |

TB/HIV care in new and relapse TB patients, 2016

| | Number | (%) |
|---|--------|------|
| Patients with known HIV-status who are HIV-positive | 1 | 33% |
| - on antiretroviral therapy | 1 | 100% |

| Drug-resistant TB care, 2016 | New cases | Previously treated cases | Total number*** |
|---|-----------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases | | | 0 (0–2) |
| Estimated % of TB cases with MDR/RR-TB | 0% (0–52) | 0% (0–0) | |
| % notified tested for rifampicin resistance | 33% | | 1 |
| MDR/RR-TB cases tested for resistance to second-line drugs | | | 0 |
| Laboratory-confirmed cases | | MDR/RR-TB: 0, XDR-TB: 1 | |
| Patients started on treatment **** | | MDR/RR-TB: 0, XDR-TB: 0 | |

| Treatment success rate and cohort size | Success | Cohort |
|--|---------|--------|
| New cases registered in 2015 | | |
| Previously treated cases registered in 2015 | | |
| HIV-positive TB cases registered in 2015 | | |
| MDR/RR-TB cases started on second-line treatment in 2014 | | 0 |
| XDR-TB cases started on second-line treatment in 2014 | | 0 |

TB preventive treatment, 2016

| | |
|---|----|
| % of HIV-positive people (newly enrolled in care) on preventive treatment | 3% |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | |

TB financing, 2017

| | |
|------------------------------------|----|
| National TB budget (US\$ millions) | <1 |
|------------------------------------|----|

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive

— MDR/RR-TB

— XDR-TB